Company Profile
MacroGenics Stock Price, News & Analysis
Company overview
Business overview
MacroGenics is a biopharmaceutical company focused on advancing a pipeline of therapeutic programs. Investors usually track how clinical data, regulatory milestones, and launch execution change the story over time.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, MacroGenics is followed within the biotech universe for its exposure to catalyst-driven execution.
Business Model Characteristics
MacroGenics follows a catalyst-driven model where the market watches how the company turns development work into repeatable value creation.
Position Within the Biotechnology Landscape
Compared with more mature healthcare peers, MacroGenics sits closer to the development side of the biotechnology landscape, where timing around data and approvals matters most.
Why the stock is moving
MGNX is trading with a steady catalyst profile while investors wait for the next headline that changes the story.
Future catalysts
MacroGenics’ next three months are about its antibody and bispecific pipeline, especially whether the company can keep advancing programs that still have partnering or development value. Investors will watch for any data that show the platform can still produce differentiated oncology assets.
Recent news
The five most recent feed items are shown below in reverse chronological order.
- 01
MacroGenics to Sell GMP Manufacturing Operations to Bora Pharmaceuticals
Source: MacroGenics
- 02
- 03
- 04
MacroGenics to Participate in the Stifel 2025 Healthcare Conference
Source: MacroGenics
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.